Attention: This platform is in beta mode. Expect some changes and adjustments.

AI Market Mood: Stock Dashboard

ENGN


Fundamental

Company: enGene Holdings Inc
Sector: Healthcare
Industry: Biotechnology
Country: Canada
Exchange: NASD
Index: -
P/E: -
EPS (ttm): -1.65
Insider Own: 57.21%
Shs Outstand: 51.07M
Perf Week: 3.51%
Market Cap: 195.73M
Forward P/E: -
EPS next Y: -2.21
Insider Trans: 0.00%
Shs Float: 21.87M
Perf Month: 2.41%
Enterprise Value: 3.63M
PEG: -
EPS next Q: -0.50
Inst Own: 40.70%
Short Float: 0.11%
Perf Quarter: 2.41%
Income: -79.88M
P/S: -
EPS this Y: -36.24%
Inst Trans: -26.93%
Short Ratio: 0.25
Perf Half Y: -46.06%
Sales: 0.00M
P/B: 0.86
EPS next Y Percentage: -10.98%
ROA: -29.57%
Short Interest: 0.02M
Perf YTD: -42.41%
Book/sh: 4.45
P/C: 0.90
EPS next 5Y: -8.93%
ROE: -33.97%
52W High: 11.00 -65.18%
Perf Year: -57.21%
Cash/sh: 4.26
P/FCF: -
EPS past 3/5Y: -367.33% -
ROIC: -32.12%
52W Low: 2.65 44.53%
Perf 3Y: -
Dividend Est.: -
EV/EBITDA: -
Sales past 3/5Y: - -
Gross Margin: -
Volatility W: 9.23%
Volatility M: 7.44%
Perf 5Y: -
Dividend TTM: -
EV/Sales: -
EPS Y/Y TTM: 69.23%
Oper. Margin: -
ATR (14): 0.29
Perf 10Y: -
Dividend Ex-Date: Aug 03, 2015
Quick Ratio: 12.66
Sales Y/Y TTM: -
Profit Margin: -
RSI (14): 56.57
Recom: 1.27
Dividend Gr. 3/5Y: - -
Current Ratio: 12.66
EPS Q/Q: -33.19%
SMA20: 4.19%
Beta: -0.41
Target Price: 21.27
Payout: -
Debt/Eq: 0.11
Sales Q/Q: -
SMA50: 5.24%
Rel Volume: 0.97
Prev Close: 3.79
Employees: 57
LT Debt/Eq: 0.09
Earnings: Jun 12 BMO
SMA200: -31.98%
Avg Volume: 93.89K
Price: 3.83
IPO: Feb 01, 2022
Option/Short: No / Yes
EPS/Sales Surpr.: -2.55% -
Trades:
Volume: 91,113
Change: 1.06%

Technical:


Latest News:

Wells Fargo & Company Initiates Coverage on enGene (NASDAQ:ENGN) - Defense World somewhat bullish
ENGN

Summary: Wells Fargo & Company initiated coverage on enGene (NASDAQ:ENGN) with an overweight rating and a $30.00 price target. Several other research firms have also given positive ratings and price targets on the stock. Insiders recently sold shares of enGene. Institutional investors have been actively acquiring stakes in the company.

Full article
2024-04-23T13:50:50Z
Wells Fargo Initiates Coverage of enGene Holdings (ENGN) with Overweight Recommendation very bullish
ENGN

Summary: Wells Fargo initiated coverage of enGene Holdings (NasdaqCM:ENGN) with an Overweight recommendation, projecting a 145.66% upside based on the average one-year price target of $36.21. Various major shareholders hold significant ownership stakes in the company.

Full article
2024-04-22T22:24:28Z